(193 days)
Not Found
No
The summary describes a mechanical interbody fusion device made of titanium alloy, with no mention of software, algorithms, or any AI/ML related terms or functionalities.
Yes.
The device is an interbody fusion device intended for use in patients with degenerative disc disease, which is a medical condition. Its purpose is to provide structural stability and is used in a surgical context, indicating a therapeutic intent.
No
The device is an interbody fusion device intended for structural stability after discectomy, not for diagnosing medical conditions.
No
The device description explicitly states it is manufactured from titanium alloy and describes physical features like protrusions and expansion capabilities, indicating it is a physical implant, not software.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health. These tests are performed outside of the body (in vitro).
- PROW FUSION-V's Function: PROW FUSION-V is an implantable surgical device. It is a physical structure designed to be placed inside the body (in vivo) to provide structural support and facilitate bone fusion in the spine. It does not perform any diagnostic tests on bodily samples.
The description clearly outlines its use as a physical implant for spinal fusion, not a diagnostic test.
N/A
Intended Use / Indications for Use
PROW FUSION-V is an interbody fusion device intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis at the involved level(s).
PROW FUSION-V is to be filled with autogenous bone graft material. The device is intended to be used with supplemental fixation.
Product codes
MAX
Device Description
PROW FUSION-V is lumbar interbody fusion devices used to provide structural stability in skeletally mature individuals following discectomy. PROW FUSION-V is provided in different shapes to fit the anatomical needs of a wide variety of patients and can expand to the desired height or the desired lordosis.
Protrusions on the superior and inferior surfaces of each device grip the endplates of the adiacent vertebrae to resist expulsion. The devices require the use of commercially available supplemental spinal fixation systems.
PROW FUSION-V is manufactured from titanium alloy per ASTM F136.
PROW FUSION-V is to be filled with autogenous bone graft material.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
lumbosacral spine (L2-S1)
Indicated Patient Age Range
skeletally mature
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Mechanical testing consisting of static and dynamic compression, static and dynamic compression-shear according to ASTM F2077 and subsidence according to ASTM F2267 was conducted in accordance with "Class II Special Controls Guidance Document: Intervertebral Fusion Device", June 12, 2007 to demonstrate substantial equivalence to the predicate. Cadaveric study conducted to evaluate proper placement of the device, graft containment and no damage to the vertebral endplate. In addition, max expansion force and wear particle assessment testing were also performed.
Key Metrics
Not Found
Predicate Device(s)
K123231, K080537, K141665, K113447
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other. The profiles are depicted in a simple, flowing line style.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 11, 2016
NLT Spine, Ltd. % John Smith, M.D., J.D. Hogan Lovells US LLP 555 Thirteenth Street, N.W. Washington, District of Columbia 20004
Re: K153786
Trade/Device Name: PROW FUSION-V Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: June 15, 2016 Received: June 15, 2016
Dear Dr. Smith:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
510(k) Number (if known)
Device Name
PROW FUSION-V
Indications for Use (Describe)
PROW FUSION-V is an interbody fusion device intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis at the involved level(s).
PROW FUSION-V is to be filled with autogenous bone graft material. The device is intended to be used with supplemental fixation.
区 Prescription Use (Part 21 CFR 801 Subpart D)
□ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for NLT Spine. The logo features a stylized spine graphic on the left, with the text "NLT SPINE" in a bold, sans-serif font to the right. Below "NLT SPINE" is the text "NonLinear Technologies" in a smaller, lighter font. The spine graphic is composed of several blue squares stacked vertically, with a curved gray line running along the side to represent the natural curve of the spine.
510(k) SUMMARY
NLT SPINE's PROW FUSION-V
As required by 21 C.F.R. § 807.92
Sponsor:
NLT SPINE Ltd. 6 Yad Harutzim St. Kfar-Saba Israel 4464103
Contact Person:
Eti Zinger VP Regulatory Affairs NLT SPINE Ltd. Tel: +972-3-6344514 Fax: +972-3-6341599 Eti.z@nlt-spine.com
Date Prepared: July 7, 2016
Name and Classification:
| Name of Device: | PROW FUSION-V |
|---|---|
| Common or Usual Name: | Intervertebral body fusion device |
| Classification Name: | Intervertebral body fusion device |
| Classification: | 21 CFR §880.3080 |
| Product Code: | MAX |
| Class: | II |
Primary Predicate Device:
Globus Medical, CALIBER Spacer (K123231)
Additional Predicate devices:
SpineSource, Inc. L-Varlock Lumbar Cage (K080537); NuVasive CoRoent System (K141665) Globus Medical, RISE Spacer (K113447)
Intended Use / Indications for Use
4
Image /page/4/Picture/0 description: The image contains the logo for NLT Spine NonLinear Technologies. The logo features a stylized spine graphic on the left, with a curved line and blue squares representing vertebrae. To the right of the spine graphic, the text "NLTSPINE" is displayed in a bold, sans-serif font, with "NonLinear Technologies" written in a smaller font size below it.
PROW FUSION-V is an interbody fusion device intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
PROW FUSION-V is to be filled with autogenous bone graft material. The device is intended to be used with supplemental fixation.
Technological Characteristics
PROW FUSION-V is lumbar interbody fusion devices used to provide structural stability in skeletally mature individuals following discectomy. PROW FUSION-V is provided in different shapes to fit the anatomical needs of a wide variety of patients and can expand to the desired height or the desired lordosis.
Protrusions on the superior and inferior surfaces of each device grip the endplates of the adiacent vertebrae to resist expulsion. The devices require the use of commercially available supplemental spinal fixation systems.
PROW FUSION-V is manufactured from titanium alloy per ASTM F136.
PROW FUSION-V is to be filled with autogenous bone graft material.
Performance Data
Mechanical testing consisting of static and dynamic compression, static and dynamic compression-shear according to ASTM F2077 and subsidence according to ASTM F2267 was conducted in accordance with "Class II Special Controls Guidance Document: Intervertebral Fusion Device", June 12, 2007 to demonstrate substantial equivalence to the predicate. Cadaveric study conducted to evaluate proper placement of the device, graft containment and no damage to the vertebral endplate. In addition, max expansion force and wear particle assessment testing were also performed.
Substantial Equivalence
PROW FUSION-V is similar to the predicates with respect to technical characteristics, performance and intended use. The information provided within this premarket notification supports substantial equivalence of the subject PROW FUSION-V to the predicate devices.